All | ASV Tertiles | P | |||
---|---|---|---|---|---|
T1 | T2 | T3 | |||
N | 1,398 | 465 | 468 | 465 | |
ASV, kg* | 2.33 [1.69] | 1.43 [0.52] | 2.33 [0.48] | 3.90 [1.58] | < 0.0001 |
DCCT group: intensive treatment, n (%) | 693 (50) | 187 (40) | 225 (48) | 281 (60) | < 0.0001 |
Duration of DCCT follow-up, years | 6.2 ± 1.8 | 6.0 ± 1.7 | 6.4 ± 1.8 | 6.1 ± 1.8 | 0.0002 |
Duration of EDIC follow-up, years | 20.0 ± 3.3 | 20.1 ± 3.0 | 20.0 ± 3.3 | 19.9 ± 3.5 | 0.50 |
Sex: male, n (%) | 733 (52) | 260 (56) | 265 (57) | 208 (45) | 0.0002 |
Age, years | 33 ± 7 | 34 ± 7 | 34 ± 7 | 32 ± 7 | < 0.0001 |
BMI, kg/m2 | 25.8 ± 3.8 | 24.2 ± 2.7 | 25.8 ± 3.2 | 27.4 ± 4.7 | < 0.0001 |
Duration of diabetes, years | 12 ± 5 | 12 ± 5 | 13 ± 5 | 12 ± 5 | 0.0005 |
HbA1c, % | 8.3 ± 1.6 | 8.3 ± 1.6 | 8.3 ± 1.6 | 8.2 ± 1.7 | 0.24 |
HbA1c, mmol/mol | 67 ± 18 | 68 ± 17 | 67 ± 17 | 66 ± 19 | 0.24 |
Systolic BP, mmHg | 117 ± 12 | 117 ± 12 | 117 ± 12 | 116 ± 11 | 0.28 |
Diastolic BP, mmHg | 75 ± 9 | 74 ± 9 | 75 ± 9 | 74 ± 9 | 0.25 |
Arterial hypertension, n (%) | 57 (4.1) | 11 (2.4) | 26 (5.6) | 20 (4.3) | 0.05 |
Total cholesterol, mmol/L | 4.72 ± 0.89 | 4.65 ± 0.85 | 4.68 ± 0.80 | 4.82 ± 0.96 | 0.007 |
LDL-cholesterol, mmol/L | 2.94 ± 0.77 | 2.88 ± 0.74 | 2.92 ± 0.76 | 3.02 ± 0.80 | 0.02 |
HDL-cholesterol, mmol/L | 1.33 ± 0.34 | 1.35 ± 0.35 | 1.32 ± 0.34 | 1.32 ± 0.32 | 0.20 |
Triglycerides, mmol/L* | 0.83 [0.49] | 0.75 [0.48] | 0.83 [0.52] | 0.88 [0.53] | < 0.0001 |
Hyperlipidemia, n (%) | 387 (28) | 106 (23) | 139 (30) | 142 (31) | 0.01 |
eGFR, ml/min/1.73m2 | 117 ± 13 | 116 ± 12 | 116 ± 12 | 119 ± 14 | 0.008 |
UAE, mg/24 h* | 10 [12] | 9 [9] | 10 [13] | 9 [13] | 0.02 |
UAE > 30 mg/24 h, n (%) | 149 (11) | 41 (9) | 66 (14) | 42 (9) | 0.01 |
Tobacco smoking, n (%) | 278 (20) | 83 (18) | 88 (19) | 107 (23) | 0.10 |
Family history of MI, n (%) | 681 (49) | 220 (47) | 230 (49) | 231 (50) | 0.74 |
Family history of T2D, n (%) | 126 (9) | 38 (8) | 41 (9) | 47 (10) | 0.57 |